Drug Trial Radar · NCT03300518
Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Nov 15, 2017
Primary completion
Jun 18, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- Reproductive & Genetic Hospital of CITIC-XiangyaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 3, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to assess the efficacy of add-on estrogen pretreatment in GnRH antagonist protocol on oocyte retrieval as compared with GnRH antagonist protocol for patients with poor ovarian response Add-on estrogen pretreatment protocol is superior to none pretreatment GnRH antagonist protocol for the number of oocytes retrieval
Conditions
- Infertility
Interventions
Follitropin Beta;MSDDrug
Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
GanirelixDrug
A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
hCGDrug
Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
estradiol valerateDrug
Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of oocytes retrieved by the IVG 36 hours after hCG administrationTime frame: 36 hours after hCG administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Reproductive & Genetic Hospital of Citic-Xiangya
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.